Abraham Avigdor

机构：Tel Aviv University, Sheba Medical Center · ORCID：0000-0002-7448-869X

发表论文 255 篇 · 总被引 6362 次 · h-index 40

代表论文

• Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial (2025 · Journal of Clinical Oncology · 被引 13)
• Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (2025 · Blood · 被引 1)
• Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma (2025 · Cancer Research · 被引 1)
• Cladribine-Based Salvage Therapy in Relapsed/Refractory AML: A Multicenter Retrospective Study (2026 · Leukemia Research)
• Table S11 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma (2026)
• Figure S1 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma (2026)